Meclizine HCl Tablets, USP, 12.5 mg, 100 Tablets bottles, Rx Only, Mfd. for: Wilshire Pharmaceuticals, Inc., Atlanta, GA 30328, Product of India, NDC 52536-129-01
Wilshire Pharmaceuticals
Failed Dissolution Specifications
Prescription and over-the-counter medications
Wilshire Pharmaceuticals
Failed Dissolution Specifications
Labeling: Label Mix-Up. THe English label with Drug Facts panel for Camphor was incorrectly placed on product.
Failed Dissolution Specifications
CGMP Deviations: Individual Unidentified impurities results of the product was found at higher side of the specification limit.
CGMP Deviations: Individual Unidentified impurities results of the product was found at higher side of the specification limit.
Chemical Contamination: Products contain methanol and were below the label claim for ethanol content
Chemical Contamination: Products contain methanol and were below the label claim for ethanol content
Chemical Contamination: Products contain methanol and were below the label claim for ethanol content
Chemical Contamination: Products contain methanol and were below the label claim for ethanol content
Wilshire Pharmaceuticals
Failed Dissolution Specifications
Labeling; Label Mixup; syringe barrels may containing markings for 150 mg/mL (corresponding to 120 mg/0.8mL strength) instead of 100 mg/mL markings (corresponding to 100 mg/mL strength)
SUN PHARMACEUTICAL INDUSTRIES
Failed Impurity/Degradation Specifications
Stanley Specialty Pharmacy Compounding and Wellness Center
Superpotent Drug. Lidocaine higher concentration than listed
Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials
Labeling; Label Mixup; syringe barrels may contain markings for 100 mg/mL (corresponding to 100 mg/mL strength) instead of 150 mg/mL (corresponding to 120 mg/0.8mL strength)
Nostrum Laboratories
CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level.
Failed Impurities/Degradation Specifications; Out-of-specification test results observed for Impurity C at 9 month long-term stability time point.
Taro Pharmaceuticals U.S.A.
CGMP deviations.
Discoloration and failed pH specifications
Bausch Health Companies
Failed Impurities/Degradation Specifications:Out of specification during the 24 month stability testing of Impurity D.